News|Articles|November 16, 2026

Cretostimogene Cuts Recurrence Risk in Intermediate-Risk, High-Grade Ta NMIBC

Fact checked by: Roman Fabbricatore

Adjuvant cretostimogene reduced recurrence risk by 68% vs surveillance in intermediate-risk and high-grade Ta NMIBC in the phase 3 PIVOT-006 trial.

Adjuvant intravesical cretostimogene grenadenorepvec significantly improved recurrence-free survival (RFS) compared with surveillance following complete tumor resection in patients with intermediate-risk and high-grade Ta (≤3 cm) non–muscle-invasive bladder cancer (NMIBC), meeting the primary end point of the phase 3 PIVOT-006 trial (NCT06111235), according to a news release from CG Oncology.1

Treatment with the investigational oncolytic immunotherapy reduced the risk of recurrence by 68%, and no grade 3 or higher treatment-related adverse events (TRAEs) were reported. Topline results will be presented as a late-breaking podium presentation at the Society of Urologic Oncology (SUO) Annual Meeting on December 2, 2026.

What were the topline results of the PIVOT-006 trial?

At a median follow-up of 17 months as of October 26, 2026, cretostimogene yielded a hazard ratio (HR) for recurrence of 0.32 (95% CI, 0.23-0.45; P <.0001) vs the surveillance control arm. According to the company, the RFS benefit was observed across both patients with high-grade disease and those with low-grade disease.

Cretostimogene was generally well tolerated, and its safety profile was consistent with findings from prior studies of the agent. No grade 3 or higher TRAEs and no treatment-related discontinuations occurred.

“For patients with intermediate-risk and high-grade Ta NMIBC, reducing recurrence is a meaningful clinical objective because recurrence can bring additional invasive procedures and continued disease burden,” stated Vijay Kasturi, MD, chief medical officer of CG Oncology, in the news release.1 “These data give us the opportunity to change clinical practice and help more people remain cancer-free longer while reducing the burden of their disease.”

How was the PIVOT-006 trial designed?

PIVOT-006 is a randomized phase 3 study that enrolled 367 patients at approximately 90 sites in the US and Canada. Enrolled patients represented the range of disease types specified in American Urological Association (AUA)/SUO guidelines at study start, including recurrent low-grade Ta disease (within 12 months), solitary low-grade Ta tumors larger than 3 cm, multifocal low-grade Ta disease, solitary high-grade Ta tumors 3 cm or smaller, and low-grade T1 disease.

Eligible patients had histologically confirmed intermediate-risk NMIBC per AUA/SUO definitions diagnosed within 90 days of randomization, were 18 years or older, had an ECOG performance status of 0 to 2, and had no nodal or metastatic disease at screening.2 Patients were randomly assigned 1:1 to receive intravesical cretostimogene following transurethral resection of bladder tumor (TURBT) or surveillance, with stratification by receipt of single-dose perioperative chemotherapy and tumor grade.

Cretostimogene was administered with the transduction-enhancing agent n-dodecyl-β-D-maltoside (DDM) as a 6-dose weekly induction course, followed by 3 weekly maintenance doses at months 3 and 6 and single doses at months 9 and 12. Patients in the surveillance arm could receive cretostimogene upon intermediate-risk recurrence.

RFS served as the primary end point, and the trial was designed to detect a 10% absolute improvement in 12-month RFS with 90% power. Secondary end points include safety, tolerability, progression-free survival, and time to next intervention, with health-related quality of life and biomarker analyses as exploratory end points.3

What is cretostimogene and where does it stand with the FDA?

Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy that has been evaluated in more than 700 patients with NMIBC across its clinical development program. The program includes 2 phase 3 trials: PIVOT-006 and BOND-003, which is evaluating the agent in patients with Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC.

The FDA previously granted fast track and breakthrough therapy designations to cretostimogene for the treatment of patients with BCG-unresponsive NMIBC. The agent is also being assessed in the multicohort phase 2 CORE-008 trial (NCT06567743), which includes patients with BCG-exposed high-risk, BCG-naive high-risk, and BCG-unresponsive NMIBC, and is available through an expanded access program in North America for eligible patients with BCG-unresponsive disease.

According to the company, there are currently no FDA-approved adjuvant treatment options for the approximately 50,000 patients in the US with intermediate-risk and high-grade Ta NMIBC.

What are the next steps for cretostimogene in NMIBC?

CG Oncology plans to submit a biologics license application (BLA) for cretostimogene in intermediate-risk and high-grade Ta NMIBC, supported by the PIVOT-006 data, in the second quarter of 2027. Following feedback from the FDA, the company stated it is broadening its initial BLA in BCG-unresponsive NMIBC to include patients with carcinoma in situ, with or without papillary tumors, as well as those with high-grade papillary-only disease; completion of that submission is expected before the end of March 2027. All manufacturing activities required for both filings have been completed, according to the company.

References

  1. PIVOT-006 phase 3 registrational trial demonstrates unprecedented improvement in recurrence-free survival (RFS) for intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). News release. CG Oncology, Inc. November 16, 2026. Accessed November 16, 2026. https://tinyurl.com/9js6s75w
  2. Svatek RS, Bivalacqua TJ, Shore ND, Jayram G, Josephson DY, Daneshmand S. PIVOT-006: a phase 3, randomized study of adjuvant intravesical cretostimogene grenadenorepvec versus surveillance for the treatment of intermediate-risk non-muscle invasive bladder cancer. Presented at: Society of Urologic Oncology 25th Annual Meeting; December 3-6, 2024; Dallas, TX. https://tinyurl.com/3v8msapr
  3. A study of adjuvant cretostimogene grenadenorepvec for treatment of intermediate risk NMIBC following TURBT. ClinicalTrials.gov. Updated July 1, 2026. Accessed November 16, 2026. https://tinyurl.com/mrx2faw3

Related to this article